|
AI Limit for Nitroso Nebivolol
|
|
11
|
2732
|
April 3, 2024
|
|
AI difference between FDA and EMA, HC and TGA
|
|
0
|
1129
|
March 22, 2024
|
|
N-Nitrosamine impurity of heterocyclic aromatic ring
|
|
16
|
3436
|
March 22, 2024
|
|
Nitroso amines quantification in drugs which are having MDD Value more than 10.0g/Day
|
|
2
|
436
|
March 20, 2024
|
|
New Validated LC-MS Method Development and Estimation of Nitrosamine impurities in Canaglifozin -Pub
|
|
0
|
777
|
February 16, 2024
|
|
N- nitroso Nitazoxanide
|
|
1
|
519
|
February 8, 2024
|
|
Reflective Beginnings: We have to be in the driver's seat
|
|
4
|
555
|
January 9, 2024
|
|
Redefining Nitrosamine Risks: A Fresh Perspective on Pharmaceuticals -Pub
|
|
16
|
2399
|
December 17, 2023
|
|
Quantification of 13 N-Nitrosamines in Pharmaceuticals using SPE-LC-MS/MS
|
|
0
|
897
|
December 13, 2023
|
|
MDD for API/DP for Ophthalmic Formulation
|
|
4
|
966
|
December 12, 2023
|
|
10º encontro Farmacopeia Brasileira
|
|
0
|
516
|
November 30, 2023
|
|
Does atmospheric NO2 influence the formation of NDMA in metformin?
|
|
2
|
613
|
November 3, 2023
|
|
Vilazodone Nitrosamine
|
|
0
|
451
|
October 31, 2023
|
|
Lumateperone tosylate NDSRI impurity
|
|
1
|
868
|
October 6, 2023
|
|
Variation requirements
|
|
2
|
449
|
October 2, 2023
|
|
🇺🇸 FDA - Recommended Acceptable Intake Limits for NDSRIs Guidance for Industry
|
|
47
|
7178
|
September 20, 2023
|
|
Nitrosamine in DS and DP specifications
|
|
2
|
854
|
September 20, 2023
|
|
Apixaban Drug Substance-Related Impurities (NDSRIs)
|
|
3
|
1480
|
September 15, 2023
|
|
Nitrite Detection at Picogram Level, is it possible?
|
|
4
|
1084
|
September 14, 2023
|
|
🇪🇺 EMA Q&A Rev. 16 EMA/409815/2020 - MAJOR UPDATE
|
|
108
|
24476
|
September 12, 2023
|
|
Strategies for Assessing Acceptable Intakes for Novel N-Nitrosamines Derived from Active Pharmaceutical Ingredients
|
|
4
|
672
|
August 23, 2023
|
|
Nitrosaminas: Estrutura química vs Potencial carcinogênico
|
|
3
|
582
|
August 23, 2023
|
|
Total impurities limit if more than one nitrosamine impurities are observed in product
|
|
4
|
678
|
August 14, 2023
|
|
Planilha CPCA na prática
|
|
0
|
462
|
August 6, 2023
|
|
The Nitrosamine “Saga”
|
|
3
|
1623
|
July 29, 2023
|
|
FDA Workshop: Mitigation Strategies for Nitrosamine Drug Substance Related Impurities
|
|
11
|
3688
|
July 27, 2023
|
|
NDSRIs: Atualizações e Desafios
|
|
0
|
468
|
July 24, 2023
|
|
Forced degradation: predicting nitrosamine formation
|
|
8
|
1796
|
July 20, 2023
|
|
Establishment of Acceptable Intakes, framework
|
|
12
|
813
|
July 12, 2023
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
2
|
2062
|
July 3, 2023
|